Want to see TSE:DOSE full AI Analyst Report?
Top Page
Rapid Dose Therapeutics Corp
(DOSE)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.13
▲(5.83% Upside)
Action:Reiterated
Date:10/01/26
The score is weighed down primarily by weak financial performance, including persistent heavy losses, negative gross profit, declining revenue, and a stressed balance sheet with negative equity. Technicals provide a partial offset with improving short-term trend signals, while valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Proprietary QuickStrip platform
A proprietary delivery platform can support differentiation across pharmaceutical, nutraceutical, and other active-compound applications. Its formulation and intellectual-property focus may create repeatable partnering opportunities and allow the company to address multiple product categories over the next several quarters.
Negative Factors
Shrinking revenue and weak profitability
Declining revenue combined with negative gross profit shows that the current business has not yet achieved healthy underlying economics. Persistent operating losses and net losses larger than revenue can consume capital, limit reinvestment, and make sustainable scale difficult over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary QuickStrip platform
A proprietary delivery platform can support differentiation across pharmaceutical, nutraceutical, and other active-compound applications. Its formulation and intellectual-property focus may create repeatable partnering opportunities and allow the company to address multiple product categories over the next several quarters.
Read all positive factors
Rapid Dose Therapeutics Corp (DOSE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$15.01M
Dividend YieldN/A
Average Volume (3M)31.76K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth4.30%
EPS Growth38.28%
CountryCA
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding136,444,840
10 Day Avg. Volume23,333
30 Day Avg. Volume31,762
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rapid Dose Therapeutics Corp Business Overview & Revenue Model
Company Description
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagshi...
How the Company Makes Money
Rapid Dose Therapeutics primarily makes money by monetizing its QuickStrip drug-delivery technology through commercial and strategic arrangements rather than by operating as a large, fully integrated drug manufacturer. Key revenue sources may incl...
Rapid Dose Therapeutics Corp Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
34
Negative
| Breakdown | May 2026 | May 2025 | May 2024 | Nov 2022 | Feb 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.77M | 2.09M | 1.02M | 718.30K | 755.20K |
| Gross Profit | -956.89K | 1.18M | 563.41K | 372.40K | 699.85K |
| EBITDA | -1.66M | -3.93M | -3.02M | -2.92M | -987.00K |
| Net Income | -3.39M | -5.40M | -4.31M | -3.81M | -1.80M |
Balance Sheet | |||||
| Total Assets | 3.28M | 1.63M | 1.89M | 2.25M | 3.83M |
| Cash, Cash Equivalents and Short-Term Investments | 11.55K | 20.72K | 161.06K | 27.59K | 70.26K |
| Total Debt | 5.32M | 2.61M | 2.45M | 1.61M | 2.06M |
| Total Liabilities | 10.46M | 6.84M | 5.04M | 4.92M | 5.41M |
| Stockholders Equity | -7.18M | -5.21M | -3.16M | -2.67M | -1.58M |
Cash Flow | |||||
| Free Cash Flow | -271.29K | -1.15M | -2.29M | -863.92K | -1.63M |
| Operating Cash Flow | -270.39K | -1.15M | -2.29M | -863.92K | -1.62M |
| Investing Cash Flow | -899.00 | -5.74K | 0.00 | 0.00 | -9.12K |
| Financing Cash Flow | 262.13K | 1.01M | 2.43M | 856.53K | 1.65M |
Rapid Dose Therapeutics Corp Technical Analysis
Positive
0.12
Price Trends
0.10
Positive
0.10
Positive
0.12
Positive
Market Momentum
<0.01
Negative
59.77
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and above the 200-day MA of 0.12, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.77 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DOSE.
Rapid Dose Therapeutics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$9.74M | 0.65 | 101.66% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$50.46M | -0.35 | -147.92% | ― | ― | 85.31% | |
46 Neutral | C$15.01M | -5.46 | 46.54% | ― | 4.30% | 38.28% | |
42 Neutral | C$12.69M | -2.43 | 92.37% | ― | ― | 16.04% | |
41 Neutral | C$33.94M | -7.42 | -101.95% | ― | 95.45% | -26.79% |
* Healthcare Sector Average
TSE:DOSE
Rapid Dose Therapeutics Corp
0.13
-0.04
-23.53%
TSE:BCT
BriaCell Therapeutics
6.10
-11.32
-64.98%
TSE:HEM
Hemostemix
0.06
-0.04
-40.00%
TSE:BLAB
Britannia Life Sciences Inc
0.06
-0.03
-29.41%
TSE:TELI
Telescope Innovations Corp
0.42
0.05
15.07%
Rapid Dose Therapeutics Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rapid Dose Therapeutics Secures Second Patent for QuickStrip Nicotine Oral Film
Positive
Aug 26, 2026
Rapid Dose Therapeutics and Aavishkar Oral Strips have secured a second Indian patent for their QuickStrip Nicotine oral-film technology, this time covering a monolayer formulation and related manufacturing processes. The new 20-year patent comple...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.